Therapeutic applications of the insulin-like growth factors

Growth Hormone and IGF Research

Volumn 14, Issue 4, 2004, Pages 301-308

  Savage, Martin O ^a,c   Camacho Hübner, Cecilia ^a   Dunger, David B ^b  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^c ST BARTHOLOMEW S HOSPITAL   (United Kingdom)

Author keywords

Diabetes mellitus; Growth hormone resistance; Idiopathic short stature; Insulin resistance; RhIGF I therapy; rhIGF I IGFBP 3 complex

Indexed keywords

ANABOLIC AGENT; GROWTH HORMONE; GROWTH HORMONE RECEPTOR; GROWTH PROMOTOR; RECOMBINANT SOMATOMEDIN C; SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN C RECEPTOR;

ANOREXIA; ARTHRALGIA; BODY HEIGHT; CHRONIC INFLAMMATION; CLINICAL TRIAL; COARSE FACE; CONVULSION; CROHN DISEASE; CYSTIC FIBROSIS; DOSE RESPONSE; DRUG EFFICACY; DRUG MECHANISM; DRUG TARGETING; EDEMA; FACE PAIN; FACIAL NERVE PARALYSIS; GENE DELETION; GLUCOSE METABOLISM; GROWTH HORMONE DEFICIENCY; GROWTH RATE; HEADACHE; HIRSUTISM; HUMAN; HYPOGLYCEMIA; INJECTION PAIN; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN METABOLISM; INSULIN RESISTANCE; INSULIN SENSITIVITY; INTRACRANIAL HYPERTENSION; JAW DISEASE; JUVENILE RHEUMATOID ARTHRITIS; KIDNEY HYPERTROPHY; LIPOHYPERTROPHY; NON INSULIN DEPENDENT DIABETES MELLITUS; NUTRITIONAL DISORDER; OBESITY; PAPILLEDEMA; PRIORITY JOURNAL; RETROSPECTIVE STUDY; REVIEW; SHORT STATURE; SIGNAL TRANSDUCTION; SPLENOMEGALY; TONSIL DISEASE;

ADOLESCENT; ADULT; DIABETES MELLITUS; GENETIC DISEASES, INBORN; GROWTH DISORDERS; HUMANS; INSULIN RESISTANCE; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 3; LARON SYNDROME; MALE; RECOMBINANT PROTEINS; SOMATOMEDINS;

EID: 3042773859     PISSN: 10966374     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ghir.2004.04.001     Document Type: Review

References (66)

1. Woods K.A. Savage M.O. IGF-deficiency Rosenfeld In: R.G. Roberts C.T. (Eds.) IGF in Health and Disease 2000 651-674 The Humana Press Inc. Totowa, USA
2. Woods K.A. Camacho-Hübner C. Savage M.O. Clark A.J.L. Intrauterine growth retardation and post-natal growth failure associated with deletion of the insulin-like growth factor-I gene New Engl. J. Med. 355 1996 1363-1367
3. Camacho-Hübner C. Woods K.A. Miraki-Moud F. et al. Effects of recombinant human insulin-like growth factor-I (IGF-I) therapy on the growth hormone-IGF system of a patient with partial IGF-I gene deletion J. Clin. Endocrinol. Metab. 84 1999 1611-1616
4. Woods K.A. Camacho-Hübner C. Bergman R.N. Barter D. Clark A.J.L. Savage M.O. Effects of insulin-like growth factor I (IGF-I) therapy on body composition and insulin resistance in IGF-I gene deletion J. Clin. Endocrinol. Metab. 85 2000 1407-1411
5. Pereira Arias A.M. Walenkamp M.-J.E. Hilhorst-Hofstee Y. et al. Clinical and biochemical expression of a homozygous missense mutation in the IGF-1 gene Endocrine Soc. 2003 P2-358
6. Savage M.O. Blum W.F. Ranke M.B. et al. Clinical and endocrine status in patients with growth hormone insensitivity (Laron syndrome) J. Clin. Endocrinol. Metab. 77 1993 1465-1471
7. Rosenfeld R.G. Rosenbloom A.L. Guevara-Aguirre J. Growth hormone (GH) insensitivity due to primary GH receptor deficiency Endoc. Rev. 15 1994 369-390
8. Rosenbloom A.L. Guevara J. Rosenfeld R.G. Fielder P.J. The little women of Loja - growth hormone receptor deficiency in an inbred population of Southern Ecuador New Engl. J. Med. 323 1990 1367-1374
9. Woods K.A. Dastot F. Preece M.A. et al. Phenotype: genotype relationships in growth hormone insensitivity syndrome J. Clin. Endocrinol. Metab. 82 1997 3529-3535
10. Kofoed E.M. Hwa V. Little B. et al. Growth hormone insensitivity associated with a STAT5b mutation N. Engl. J. Med. 349 2003 1110-1112
11. Burren C.P. Woods K.A. Rose S.J. et al. Clinical and endocrine characteristics in atypical and classical growth hormone insensitivity syndrome Horm. Res. 55 2001 125-130
12. Bjarnason R. Banerjee K. Rose S.J. et al. Spontaneous growth hormone secretory characteristics in children with partial growth hormone insensitivity Clin. Endocrinol. 57 2002 357-361
13. Laron Z. Lilos P. Klinger B. Growth curves for Laron syndrome Arch. Dis. Child 68 1993 768-770
14. Rosenbloom A.L. IGF-I treatment of growth hormone insensitivity In: Rosenfeld R.G. Roberts C.T. (Eds.) IGF in Health and Disease 2000 739-770 The Humana Press Inc. Totowa, USA
15. Laron Z. Erster B. Klinger B. Anin S. Effect of acute administration of insulin-like growth factor I in patients with Laron-type dwarfism Lancet ii 1988 1170-1172
16. Walker J.L. Ginalska-Malinovska M. Romer T.E. Pucilowska J.B. Underwood L.E. Effects of the infusion of insulin-like growth factor I in a child with growth hormone insensitivity syndrome (Laron dwarfism) N. Engl. J. Med. 324 1991 1483-1488
17. Grahnen A. Kastrup K. Heinrich U. et al. Pharmacokinetcis of recombinant human insulin-like growth factor I given subcutaneously to healthy volunteers and to patients with growth hormone receptor deficiency Acta Paediatr. 391 Suppl. 1993 9-13
18. Cotterill A.M. Camacho-Hübner C. Holly J.M.P. Savage M.O. The effect of recombinant human insulin-like growth factor-I treatment on growth hormone secretion in two subjects with growth hormone insensitivity (Laron syndrome) Clin. Endocrinol. 39 1993 119-122
19. Laron Z. Anin S. Klipper-Aurbach Y. Klinger B. Effects of insulin-like growth factor on linear growth, head circulmference and body fat in patients with Laron-type dwarfism Lancet 339 1992 1258-1261
20. Guevara-Aguirre J. Vasconez O. Martinez V. et al. A randomized, double-blind, placebo controlled trial on safety and efficacy of recombinant human insulin-like growth factor-I in children with growth hormone receptor deficiency J. Clin. Endocrinol. Metab. 80 1995 1393-1398
21. Ranke M.B. Savage M.O. Chatelain P.G. et al. Insulin-like growth factor (IGF)-I improves height in growth hormone insensitivity. Two year's results Horm. Res. 44 1995 253-264
22. Backeljauw P.F. Underwood L.E. The GHIS collaborative group. Prolonged treatment with recombinant insulin-like growth factor-I in children with growth hormone insensitivity syndrome - a clinical research center study J. Clin. Endocrinol. Metab. 81 1996 3312-3317
23. Ranke M.B. Savage M.O. Chatelain P.G. Preece M.A. Rosenfeld R.G. Wilton P. Treatment of growth hormone insensitivity syndrome with insulin-like growth factor-I: long-term results of the European multicentre study Horm. Res. 51 1999 128-134
24. Backeljauw P.F. Underwood L.E. The GHIS collaborative group. Therapy for 6.5-7.5 years with recombinant insulin-like growth factor I in children with growth hormone insensitivity syndrome: a clinical research center study J. Clin. Endocrinol. Metab. 86 2001 1504-1510
25. Guevara-Aguirre J. Rosenbloom A.L. Vasconez O. Martinez V. Gargosky S.E. Rosenfeld R.G. Two year treatment of growth hormone receptor deficiency (GHRD) with recombinant insulin-like growth factor - I in 22 children: comparison of two dosage levels and to GH treated GH deficiency J. Clin. Endocrinol. Metab. 82 1997 629-633
26. Ranke M.B. Treatment of growth hormone insensitivity syndrome (GHIS) with insulin-like growth factor (IGF-I) In: Ross R.J.M. Savage M.O. (Eds.) Growth Hormone Resistance Bailliere's Clin. Endocrinol. Metab. 10 3 1996 401-410
27. Azcona C. Preece M.A. Rose S.J. et al. Growth response to rhIGF-I 80 μg/kg twice daily in children with growth hormone insensitivity syndrome: relationship to severity of clinical phenotype Clin. Endocrinol. 51 1999 787-792
28. Gabbay R.A. Moses A.C. IGF in the treatment of diabetes In: Rosenfeld R.G. Roberts C.T. (Eds.) IGF in Health and Disease 2000 721-737 The Humana Press Inc. Totowa, USA
29. Clayton K.L. Holly J.M. Carlsson L.M. et al. Loss of the normal relationships between growth hormone, growth hormone-binding protein and insulin-like growth factor-I in adolescents with insulin-dependent diabetes mellitus Clin. Endocrinol. 41 1994 517-524
30. Shishko P.I. Dreval A.V. Abugova I.A. Zajamy I.U. Goncharov V.C. Insulin-like growth factors and binding proteins in patients with recent onset type I diabetes mellitus: influence of diabetes control and intraportal insulin infusion Diabetes Res. Clin. Pract. 25 1995 1-2
31. Cheetham T.D. Holly J.M. Clayton K.L. Cwyfan-Hughes S. Dunger D.B. The effects of repeated daily recombinant human insulin-like growth factor I administration in adolescents with type I diabetes Diabetic Med. 12 1995 885-892
32. Acerini C.L. Patton C.M. Savage M.O. Kernell A. Westphal O. Dunger D.B. Randomised placebo-controlled trial of human recombinant insulin-like growth factor plus intensive insulin therapy in adolescents with insulin-dependent diabetes mellitus Lancet 350 1997 1199-1204
33. Carroll P.V. Christ E.R. Umpleby A.M. et al. IGF-I treatment in adults with type I diabetes. Effects on glucose and protein metabolism in the fasting state and during a hyperinsulinemic-euglycemic amino acid clamp Diabetes 49 2000 789-796
34. Simpson H.L. Jackson N.C. Shojaee-Moradie et al. Insulin-like growth factor I has a direct effect on glucose and protein metabolism, but no effect on lipid metabolism in type 1 diabetes J. Clin. Endocrinol. Metab. 89 2004 425-432
35. Crowne E.C. Samra J.S. Cheetham T. et al. The role of IGF-binding proteins in mediating the effects of recombinant human IGF-I on insulin requirements in type 1 diabetes mellitus J. Clin. Endocrinol. Metab. 86 2001 3686-3691
36. Zenobi P.D. Jaeggi-Groisman S.E. Riesen W.F. Roder M.E. Froesch E.R. Insulin-growth factor-I improves glucose and lipid metabolism in type 2 diabetes mellitus J. Clin. Invest. 90 1992 2234-2241
37. Schalch D.S. Turman N.J. Marcsisin V.S. Heffernan M. Guler H.P. Short-term effects of recombinant human insulin-like growth factor-I of metabolic control of patients with type II diabetes J. Clin. Endocrinol. Metab. 77 1993 1563-1568
38. Jabri N. Schalch D.S. Schwartz S.L. et al. Adverse effects of recombinant human insulin-like growth factor I in obese insulin-resistant type II diabetic patients Diabetes 53 1994 369-374
39. Moses A.C. Young S.C.J. Morrow L.A. O'Brien M. Clemmons D.R. Recombinant human insulin-like growth factor-I increases insulin sensitivity and improves glycemic control in type II diabetes Diabetes 45 1996 91-100
40. Moses A.C. Philips L. Martha P. Compton P. Zysow B for the RINDS and RICS groups. RhIGF-I improves coronary risk factors in type II diabetes (abstract) Diabetologia 40 Suppl. 1 1997 1484
41. Tritos N.A. Mantzoros C.S. Clinical review 97: syndromes of severe insulin resistance J. Clin. Endocrinol. Metab. 83 9 1998 3025-3030
42. Kuzuya H. Matsuura N. Sakamoto M. et al. Trial of insulin like growth factor I therapy for patient with extreme insulin resistance syndromes Diabetes 42 1993 696-705
43. Quin J.D. Fisher B.M. Paterson K.R. Inoue A. Beastall G.H. MacCuish A.C. Acute response to recombinant insulin-like growth factor I in a patient with Mendenhalll's syndrome New Engl. J. Med. 323 20 1990 1425-1426
44. Nakae J. Kato M. Murashita M. Shinohara N. Tamjima T. Fujieda K. Long-term effect of recombinant human insulin like growth factor I on metabolic and growth control in patient with leprechaunism J. Clin. Endocrinol. Metab. 83 2 1998 542-549
45. Blair J.C. Savage M.O. Investigation of the growth hormone - IGF-I axis in idiopathic short stature Trends Endocrinol. Metab. 13 2002 325-330
46. Goddard A.D. Covello R. Luoh S.M. et al. Mutations of the growth hormone receptor in children with idiopathic short stature N. Engl. J. Med. 333 1995 1093-1098
47. Goddard A.D. Daowd P. Chernauseck S. et al. Partial growth hormone insensitivity: the role of growth hormone receptor mutations in idiopathic short stature J. Pediatr. 131 1997 S51-S52
48. Ayling R.M. Ross R. Towner P. et al. A dominant-negative mutation of the growth hormone receptor causes familial short stature Nat. Genet. 16 1997 13-14
49. Iida K. Takahashi Y. Kaji H. et al. Growth hormone (GH) insensitivity syndrome with high serum GH-binding protein levels caused by a heterozygous splice site mutation of the GH receptor gene producing a lack of intracellular domain J. Clin. Endocrinol. Metab. 83 1998 531-537
50. Attie K.M. Carlsson L.M. Rundle A.C. Sherman B.M. Evidence for partial growth hormone insensitivity among patients with idiopathic short sature. The national cooperative growth study J. Pediatr. 127 1995 244-250
51. Rogol A.D. Blethen S.L. Sy J.P. Veldhuis J.D. On behalf of the National Copoerative Growth Study (NGCS). Do growth hormone (GH) serial sampling, insulin-like growth factor-I (IGF-I) or auxological measurements have an advantage over stimulation testing in predicting the linear growth response to GH therapy? Clin. Endocrinol. 58 2003 229-237
52. Selva K.A. Buckway C.K. Sexton G. et al. Reproducibility in patterns of IGF generation with special reference to idiopathic short stature Horm. Res. 60 2003 237-246
53. Sjoberg M. Salazar T. Espinosa C. et al. Study of GH sensitivity in Chilean patients with idiopathic short stature J. Clin. Endocrinol. Metab. 86 2001 4375-4381
54. Blair J.C. Camacho-Hübner C. Miraki-Moud F. et al. Standard and low dose IGF-I generation tests and spontaneous growth hormone secretion in children with idiopathic short stature Clin. Endocrinol. 60 2004 163-168
55. Rakover Y. Silbergeld A. Lavi I. Masalha R. Shlomo B. Can exaggerated response to a provocative test identify patients with partial GH insensitivity syndrome? Eur. J. Endocrinol. 146 2002 319-323
56. C.E. Brain, M.O. Savage, Disturbance of growth and pubertal development in chronic inflammatory bowel disease, in: J.A. Walker-Smith, T.T. MacDonald (Eds.), Chronic Inflammatory Bowel Disease in Childhood, Baillière's Clin. Gastroenterol. (1994) 83-100
57. Beattie R.M. Camacho-Hübner C. Wacharasindhu S. Cotterill A.M. Walker-Smith J.A. Savage M.O. Responsiveness of IGF-I and IGFBP-3 to therapeutic intervention in children and adolescents with Crohn's disease Clin. Endocrinol. 48 1998 483-489
58. Street M.E. De Angelis G.L. Camacho-Hübner C. et al. Relationships between serum IGF-I, IGFBP-2, Iinterleukin-1beta and interleukin-6 in inflammatory bowel disease Horm. Res. 61 2004 159-164
59. De Benedetti F. Alonzi T. Moretta A. et al. Interleukin 6 causes growth impairment in transgenic mice through a decrease in insulin-like growth factor-I. A model for stunted growth in children with chronic inflammation J. Clin. Invest. 99 4 1997 643-650
60. Davies U.M. Jones J. Reeve J. et al. Effects of disease activity and recombinant human growth hormone on insulin-like growth factor 1, insulin-like growth factor binding proteins 1 and 3, and osteocalcin Arthrit. Rheum. 40 1997 332-340
61. Levetown M. Modulation of types I and II acute phase reactants with insulin-like growth factor-I/binding protein 3 complex in serverely burned children Crit. Care Med. 30 1 2002 255-257
62. Boonen S. Rosen C. Bouillon R. et al. Muskuloskeletal effects of the recombinant human IGF-I/IGF binding protein-3 complex in osteoporotic patients with proximal femoral fracture: a double blind, placebo-controlled pilot study J. Clin. Endocrinol. Metab. 87 4 2002 1593-1599
63. Clemmons D.R. Moses A.C. McKay M.J. Sommer A. Rosen D. Ruckle J. The combination of insulin-like growth factor I and insulin-like growth factor binding protein-3 reduces insulin requirements in insulin-dependent type I diabetes: evidence for in vivo biological activity J. Clin. Endocrinol. Metab. 85 4 2000 1518-1524
64. A.D. Rogol, W. Jacobson, A. Smith, et al., A double-blind, randomized, placebo-controlled, study to determine the dose response profile of rhIGF-I/rhIGFBP-3 in subjects with Type 2 Diabetes Mellitus requiring insulin therapy, Poster American Diabetes Association 61st Scientific Sessions, June, San Francisco, 2002
65. Saukkoman T. Amin R. Williams R.M. et al. Effects of Combined recombinant human insulin-like growth factor-I/insulin-like growth factor binding protein 3 on growth hormone secretion and insulin sensitivity in adolescent with type I diabetes (abstract) Horm. Res. 60 Suppl. 2 2003 1-175
66. Camacho-Hübner C. Storr H. Miraki-Moud F. et al. Recombinant human insulin-like growth factor (IGF)-I/IGF binding protein-3 complex administered to patients with growth hormone insensitivity syndrome (abstract) Horm. Res. 60 Suppl. 2 2003 1-175